CN104651364B - 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 - Google Patents
一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 Download PDFInfo
- Publication number
- CN104651364B CN104651364B CN201510056926.7A CN201510056926A CN104651364B CN 104651364 B CN104651364 B CN 104651364B CN 201510056926 A CN201510056926 A CN 201510056926A CN 104651364 B CN104651364 B CN 104651364B
- Authority
- CN
- China
- Prior art keywords
- lncrna
- mir
- sequence
- oncolytic adenovirus
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title claims abstract description 115
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 71
- 108700011259 MicroRNAs Proteins 0.000 title claims abstract description 48
- 230000000174 oncolytic effect Effects 0.000 title claims abstract description 41
- 230000002860 competitive effect Effects 0.000 title claims abstract description 8
- 206010007269 Carcinogenicity Diseases 0.000 title claims abstract description 7
- 231100000260 carcinogenicity Toxicity 0.000 title claims abstract description 7
- 230000007670 carcinogenicity Effects 0.000 title claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 99
- 230000014509 gene expression Effects 0.000 claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 241000700605 Viruses Species 0.000 claims abstract description 35
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 208000014018 liver neoplasm Diseases 0.000 claims description 19
- 230000033228 biological regulation Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 13
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 13
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 13
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 13
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 13
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 11
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 11
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 11
- 108091033773 MiR-155 Proteins 0.000 claims description 10
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 9
- 108091064399 miR-10b stem-loop Proteins 0.000 claims description 8
- 108091091751 miR-17 stem-loop Proteins 0.000 claims description 8
- 108091028232 Mir-184 Proteins 0.000 claims description 7
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 7
- 108091045790 miR-106b stem-loop Proteins 0.000 claims description 7
- 108091072763 miR-151 stem-loop Proteins 0.000 claims description 7
- 108091044046 miR-17-1 stem-loop Proteins 0.000 claims description 7
- 108091065423 miR-17-3 stem-loop Proteins 0.000 claims description 7
- 108091031103 miR-181a stem-loop Proteins 0.000 claims description 7
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 claims description 7
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 claims description 7
- 108091037327 miR-449 stem-loop Proteins 0.000 claims description 7
- 108091040525 miR-449a stem-loop Proteins 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 2
- 230000009456 molecular mechanism Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 32
- 108010002687 Survivin Proteins 0.000 abstract description 20
- 102000044209 Tumor Suppressor Genes Human genes 0.000 abstract description 9
- 108700025716 Tumor Suppressor Genes Proteins 0.000 abstract description 9
- 230000001629 suppression Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000009137 competitive binding Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 82
- 108091033760 Oncomir Proteins 0.000 description 31
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 18
- 108091008146 restriction endonucleases Proteins 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 108091070501 miRNA Proteins 0.000 description 12
- 101001045123 Homo sapiens Hyccin Proteins 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108091028695 MiR-224 Proteins 0.000 description 7
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 7
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 108091062157 Cis-regulatory element Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108091007065 BIRCs Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000003217 anti-cancerogenic effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 244000309459 oncolytic virus Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 3
- 108091027766 Mir-143 Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 2
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 101150101189 HCC gene Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 108091008065 MIR21 Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091007780 MiR-122 Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 108091051828 miR-122 stem-loop Proteins 0.000 description 2
- 108091050874 miR-19a stem-loop Proteins 0.000 description 2
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 2
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 2
- 108091029119 miR-34a stem-loop Proteins 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 101710178010 Baculoviral IAP repeat-containing protein 5 Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091093085 MiR-338 Proteins 0.000 description 1
- 108091028066 Mir-126 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 101150083707 dicer1 gene Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108091023663 let-7 stem-loop Proteins 0.000 description 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 1
- 108091007427 let-7g Proteins 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108091045542 miR-1-2 stem-loop Proteins 0.000 description 1
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 description 1
- 108091063409 miR-125b-2 stem-loop Proteins 0.000 description 1
- 108091040501 miR-129 stem-loop Proteins 0.000 description 1
- 108091045757 miR-129-3 stem-loop Proteins 0.000 description 1
- 108091090758 miR-129-4 stem-loop Proteins 0.000 description 1
- 108091065139 miR-129-5 stem-loop Proteins 0.000 description 1
- 108091027034 miR-148a stem-loop Proteins 0.000 description 1
- 108091026495 miR-148b stem-loop Proteins 0.000 description 1
- 108091057645 miR-15 stem-loop Proteins 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091047758 miR-185 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091054642 miR-194 stem-loop Proteins 0.000 description 1
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091090020 miR-207 stem-loop Proteins 0.000 description 1
- 108091049679 miR-20a stem-loop Proteins 0.000 description 1
- 108091090052 miR-219-1 stem-loop Proteins 0.000 description 1
- 108091061970 miR-26a stem-loop Proteins 0.000 description 1
- 108091043187 miR-30a stem-loop Proteins 0.000 description 1
- 108091072917 miR-30c-1 stem-loop Proteins 0.000 description 1
- 108091023108 miR-30e stem-loop Proteins 0.000 description 1
- 108091074487 miR-34 stem-loop Proteins 0.000 description 1
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 1
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 1
- 108091079013 miR-34b Proteins 0.000 description 1
- 108091084018 miR-34b stem-loop Proteins 0.000 description 1
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 description 1
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 description 1
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 description 1
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 description 1
- 108091090583 miR-34c stem-loop Proteins 0.000 description 1
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 description 1
- 108091071572 miR-9-2 stem-loop Proteins 0.000 description 1
- 108091050164 miR-92 stem-loop Proteins 0.000 description 1
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229930192033 plastin Natural products 0.000 description 1
- 108010049148 plastin Proteins 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Abstract
本发明涉及一种竞争性消耗致癌性microRNAs(OncomiRs)的LncRNA、溶瘤腺病毒及其用途。本发明人工合成了可联合干预多种OncomiRs的LncRNA的编码序列,以溶瘤腺病毒为载体表达该LncRNA,并利用肿瘤特异性的Survivin基因启动子调控溶瘤腺病毒增殖必需基因E1a,使病毒在癌细胞内特异性增殖复制,随腺病毒在癌细胞内特异性高拷贝复制,实现LncRNA在癌细胞内大量表达和高拷贝积累,通过与OncomiRs的靶基因竞争性结合并消耗OncomiRs,从而保护大量的抑癌基因免受OncomiRs的干扰和抑制,实现对癌细胞的靶向干预治疗,具备疗效好、安全性高的优势。
Description
技术领域
本发明涉及基因工程和病毒学技术领域,具体地说,涉及一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途。
背景技术
恶性肿瘤是以细胞异常增殖及转移为特点的一大类疾病,在我国其发病率及死亡率一直呈上升趋势,严重威胁国民的健康和生命。目前对恶性肿瘤的治疗仍以常规的手术、放疗、化疗为主,这种常规治疗对绝大多数肿瘤来说,难以收到预期的疗效,很重要的原因是没有特异的、敏感的早期诊断指标以及缺乏有效的治疗性分子靶标,这成为改善肿瘤患者临床疗效和预后的重要障碍。近年来的生物信息学分析表明,人类全部基因的三分之一都受到microRNAs(miRNAs)的调控,表明miRNAs实际上是基因调控网络中的核心成分。miRNAs分子小、数量多、作用广,甚至可以说miRNAs在细胞内、在人体内无处不在。miRNAs在多种生物进程中起到关键作用,包括调节细胞早期发育、细胞增殖、干细胞分化和凋亡。关于miRNAs对肿瘤发生发展的调控作用及其在肿瘤诊断治疗中的重要作用受到人们的关注。研究表明,miRNAs表达谱的改变参与肿瘤发生、发展的整个过程,包括肿瘤细胞的起源、侵袭及转移。因此,miRNAs对肿瘤靶向治疗的价值不可估量。
miRNAs是一类长度为18-22个核苷酸、高度保守的小分子非编码RNA,广泛存在于真核细胞中。miRNAs基因在细胞核内由RNA转录酶作用先生成miRNAs转录前体(pri-miRNAs),然后pri-miRNAs在RNA聚合酶Ⅲ作用下,剪切生成约70个核苷酸长度的miRNAs前体(pre-miRNAs)。之后,pre-miRNA被转运由细胞核进入细胞质,经过DICER酶加工,生成约18-22个核苷酸的单链RNA分子,即成熟的miRNAs。miRNAs选择性地与RNA介导的沉默复合体(RNA-induced silencing complex,RISC)特异结合,形成RISC复合物,发挥生物学功能。成熟的miRNAs可与其他蛋白质一起组成RISC复合体,通过核酸序列互补结合于靶基因mRNAs,发挥抑制靶基因mRNA翻译或降解靶基因mRNA的作用,从而发挥其对靶基因的转录后调节效应。miRNAs广泛参与生物体生命过程中的许多重要进程,包括个体发育、器官形成以及细胞增殖、分化、凋亡等,同时也参与了肿瘤的发生发展和侵袭转移。越来越多的证据表明,miRNAs的异常表达与多种恶性肿瘤密切相关。有超过一半的miRNAs位于肿瘤相关基因组区域或脆性位点、杂合性丢失区和扩增区,提示miRNAs可能作为致癌性miRNAs(致癌性microRNAs,OncomiRs)或抑癌性miRNAs而发挥作用。miRNAs有可能通过引起某些凋亡相关因子表达的变化、影响各种细胞内外信号通路的活性、调控基因转录调节因子的活性,参与肿瘤的发生发展过程中。不同人类肿瘤的miRNAs表达谱,在乳腺癌、肝癌、肺癌、大肠癌、脑瘤、白血病等多种肿瘤中均发现特异性miRNAs的高表达,这些miRNAs被视作一类OncomiRs。miR-155在慢性淋巴细胞性白血病、何杰金氏淋巴瘤、B细胞淋巴瘤、乳腺癌、肺癌、结肠癌和甲状腺癌中的表达上调,预示这些疾病患者治疗后难以缓解。miR-17-92家簇(miR-17-5p、miR-17-3p、miR-18a、miR-19a、miR-20a、miR-19b-1、miR-92-1)的高表达,可作为多发性骨髓瘤预后不良的标志物,并能够促进B细胞淋巴瘤的恶性发展。肿瘤细胞中某些miRNAs表达下调甚至缺失,也可能导致肿瘤,这类miRNAs可视作抑癌基因。如let-7表达下调与肿瘤发生有关,miR-15和miR-16与慢性淋巴细胞性白血病相关,miR-26a、miR-129、miR-143和miR-145在乳腺癌、前列腺癌、宫颈癌、淋巴系统肿瘤及大肠癌中低表达,miR-122表达下降可能介导原发性肝癌的发病过程。miR-34包括miR-34a、miR-34b和miR-34c等,在多种肿瘤中都呈现非正常的低表达。这些miRNAs表达水平的改变,与癌细胞发生发展密切相关。
以肝癌为例,通过文献检索,筛选出在肝癌中高表达的miRNAs有miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR-106b、miR-151-5p、miR-155、miR-181a/181b、miR-184,此外在乙肝病毒相关的肝癌中还可检出miR-1和miR-449a。通过比较侵袭性和非侵袭性肝癌的miRNAs表达谱,还发现20种miRNAs与肝癌转移、术后复发相关,其中上调表达的有miR-185、miR-219-1、miR-207、miR-338;下调表达的有Let-7g、miR-1-2、miR-122、miR-124a-2、miR-125b-2、miR-126、miR-148a、miR-148b、miR-15a、miR-194、miR-19a、miR-30a、miR-30c-1、miR-30e、miR-34a、miR-9-2,它们在肝癌的发生发展中分别起不同的作用。肝癌中miR-21高表达可抑制抑癌基因PTEN的表达。PTEN蛋白是3-磷酸肌醇激酶(phosphoinositide 3-kinase,PI3K)/丝/苏氨酸蛋白激酶(serine/threonine kinase,AKT)通路的重要抑制蛋白,因此,miR-21抑制PTEN的后果即是激活PI3K/AKT通路,促进癌细胞的增殖、转移。miR-221/222作用于许多关键的肿瘤抑制因子,包括Bmf、p27Kip1、p57Kip2l6、PTEN、金属蛋白酶-3的组织抑制因子TIMP-3以及DNA损伤诱导转录子4(DDIT4),从而介导肿瘤的发生发展。总之,肝癌中miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR106b、miR-151-5p、miR-155、miR-181a/181b、miR-184高表达能够促进癌细胞增殖、侵袭、转移;miR-221/222、miR-224、miR-10b、miR-155高表达能够抑制癌细胞凋亡;miR-21、miR-221/222、miR-143、miR-1、miR-449a高表达能够促进乙肝病毒增殖,诱导细胞癌变和增强癌细胞增殖活性。
肿瘤细胞与其起源的相应正常细胞之间miRNA表达谱的差异,不同肿瘤之间miRNA表达谱的特异性,以及miRNAs在肿瘤发生、发展、转移、复发过程中起到的作用,为肿瘤的生物治疗提供了有用的分子靶标,可通过调控miRNAs的表达来治疗肿瘤。近来,以miRNAs为靶点的肿瘤治疗方案有很多报道,给肿瘤的治疗带来了希望。对于在肿瘤细胞中高表达的OncomiRs,已有研究采用miRNAs抑制剂或反义序列封闭miRNAs的表达,抑制肿瘤生长。但是,现有的治疗性研究大多针对单一miRNA或者miRNAs家族。由于miRNAs作用的靶基因众多,调控机制复杂,一个miRNA可以靶向多个靶基因,一个靶基因也可能受多种miRNAs的调控,而肿瘤的发生发展一定涉及很多miRNAs分子,调控广泛的靶基因或者影响很多信号途径。因此,单一miRNA表达的干预对肿瘤的抑制效果有限,癌细胞很容易通过旁路信号途径重新获得增殖活力。
肿瘤特异性增殖腺病毒能够特异性地在肿瘤细胞内大量增殖复制,溶解破坏肿瘤细胞,释放子代病毒,感染更多的肿瘤细胞,故又称之为溶瘤腺病毒(Oncolyticadenovirus)。利用肿瘤特异性增殖腺病毒的高弥散力、高转染力以及在肿瘤细胞内特异性增殖复制的能力,可使其携带的抗癌基因拷贝数随病毒增殖而增加,在肿瘤细胞中获得高转染率、高拷贝数及高效表达的抗癌因子,提高对肿瘤的抗癌效应。由于腺病毒是目前肿瘤基因治疗的常见的、安全的病毒载体,已广泛地应用于人体基因治疗方案中,具有以下优点:基因组完全清楚,易于操作;能感染的人类细胞广泛,可高效地转导不同类型的人组织细胞,包括静止期细胞;病毒滴度较高,在细胞培养物中有高滴度的重组病毒产量;基因组大,因而可插入大片段外源基因;进入细胞内并不整合到宿主细胞基因组,因而安全性较高,无致癌性。中国国家食品药品监督管理局(SFDA)2004年和2005年已批准了2个腺病毒产品上市,临床应用至今未发现明显的毒副作用。
目前,还未见报道采用肿瘤特异性增殖腺病毒介导人工设计的LncRNA在癌细胞中特异性增殖,随腺病毒的增殖复制,以实现高拷贝、高效率表达LncRNA,提高其竞争结合miRNAs的效果,全面保护多种OncomiRs的靶基因,最终发挥更有效的抗癌效应。
发明内容
本发明的目的在于提供一种可用于肝癌等多种肿瘤治疗的竞争性消耗OncomiRs并实现多种miRNAs联合干预的LncRNA、可在癌细胞内特异性增殖复制并表达所述LncRNA的溶瘤腺病毒。
本发明提供了一种竞争性消耗OncomiRs的LncRNA,所述的LncRNA的序列为SEQ IDNO.4所示序列的n个拷贝,其中,n为大于等于1的整数。
作为本发明的一个优选例,所述的n等于6。
本发明提供了编码所述的LncRNA的编码序列,所述的LncRNA的编码序列为SEQ IDNO.1所示序列的n个拷贝,其中,n为大于等于1的整数。
作为本发明的一个优选例,所述的n等于6。
本发明提供了一种溶瘤腺病毒,所述的溶瘤腺病毒的基因组中整合有所述的LncRNA的表达盒。
作为本发明的一个优选例,所述的LncRNA的表达盒包含所述的LncRNA的编码序列,以及调控LncRNA的编码序列表达的启动子,所述的调控LncRNA的编码序列表达的启动子插入在所述LncRNA的编码序列的转录起始位点之前。
作为本发明的一个优选例,所述的溶瘤腺病毒的基因组中含有病毒增殖必需基因和调控所述病毒增殖必需基因表达的肿瘤特异性启动子。
作为本发明的一个优选例,所述的溶瘤腺病毒是以人类5型腺病毒为基础构建而成;所述的调控LncRNA的编码序列表达的启动子序列如SEQ ID NO.6所示,所述的病毒增殖必需基因序列如SEQ ID NO.8所示,所述的肿瘤特异性启动子序列如SEQ ID NO.7所示。
作为本发明的一个优选例,所述的溶瘤腺病毒的全基因组序列如SEQ ID NO.10所示。
本发明提供了所述的LncRNA、所述的LncRNA的编码序列或所述的溶瘤腺病毒在制备药物中的用途,所述的药物用于治疗肿瘤。
作为本发明的一个优选例,所述的肿瘤中miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR106b、miR-151-5p、miR-155、miR-181a/181b、miR-184、miR-1和/或miR-449a高表达。
作为本发明的一个优选例,所述的肿瘤是肝癌,特别是原发性肝细胞肝癌。
本发明提供了所述的LncRNA、所述的LncRNA的编码序列或所述的溶瘤腺病毒在制备试剂中的用途,所述的试剂用于研究肝癌细胞中的分子作用机制或/和肝癌的治疗。
本发明的优点在于提供了一种竞争性消耗OncomiRs的LncRNA、重组溶瘤腺病毒及其应用,具有以下重要意义:
1、具有多重有效的抗肿瘤机制:1)所构建的溶瘤腺病毒在肿瘤特异性Survivin基因启动子的有效控制下,能在肿瘤细胞内特异性大量增殖复制,溶解破坏肿瘤细胞,释放子代病毒感染破坏更多的肿瘤细胞;2)通过在癌细胞内持续表达人工设计的LncRNA,该LncRNA同时包含能与多个OncomiRs互补结合的序列,能够与OncomiRs的所有靶基因mRNAs竞争结合OncomiRs,从而消耗细胞内高水平的OncomiRs,对细胞内的抑癌基因起保护作用,发挥抗癌效应。这种治疗策略,可以同时有效封闭多个作用机制不同、或者作用机制互补的OncomiRs,广泛抑制OncomiRs相关的多条信号传导途径,对肿瘤的治疗更为有效,克服了单一miRNA干预对肿瘤抑制效果有限、癌细胞很容易通过旁路信号途径重新获得增殖活力的缺陷;3)以肿瘤特异性增殖溶瘤腺病毒作为载体,介导人工设计的LncRNA的表达,随着病毒在肿瘤内的特异性增殖复制,LncRNA的拷贝数和表达量呈几何倍数增长,高拷贝、高效率表达LncRNA,可大量消耗OncomiRs,对细胞内的抑癌基因显现良好的保护效果,从而抑制肿瘤发生发展乃至完全消褪。
2、具有多重有效的靶向安全机制:1)以Survivin启动子为顺式作用元件,插入腺病毒增殖必需基因E1a的转录起始位点与翻译起始位点ATG之间,调控E1a转录激活,使E1a只能特异性地在Survivin阳性的肿瘤细胞内表达,而对正常细胞没有影响或者影响极弱,其调控具有更好的可靠性和安全性;2)人工合成的LncRNA包含一组在癌细胞内高表达、能够通过多种机制促进肿瘤发生发展的OncomiRs的互补结合序列,其目标是消耗或干预OncomiRs,对癌细胞内其他的抑癌性miRNAs不起作用,正常细胞因为其OncomiRs不表达或水平极低而不会受到影响,因而使其抗肿瘤疗效得以提高,安全性得以改善;3)在LncRNA编码序列起始和终止位置引入翻译终止密码子,阻止其翻译成为任何蛋白或多肽分子。
3、本发明提供的LncRNA和腺病毒载体相结合的抗肿瘤体系适应于人类绝大多数类型恶性肿瘤的治疗,目前国内外未见类似治疗方案,可据此构建多种抗肿瘤生物治疗产品,为肿瘤治疗建立了一个疗效可靠的技术平台。
附图说明
图1.AdSVPE1a-lncR在不同细胞系中的增殖倍数比较。
图2.AdSVPE1a-lncR介导LncRNA在不同细胞系中表达水平的比较。
图3.AdSVPE1a-lncR介导LncRNA表达对细胞存活率的影响。
图4.AdSVPE1a-lncR介导LncRNA表达对细胞迁移侵袭力的影响。
图5.AdSVPE1a-lncR介导LncRNA表达对肝癌细胞基因表达谱的影响。
图6.AdSVPE1a-lncR对Huh-7肝癌细胞裸鼠移植瘤的抑瘤效果。
具体实施方式
下面结合附图对本发明提供的具体实施方式作详细说明。
本申请的发明人利用肿瘤特异性的Survivin基因启动子调控溶瘤腺病毒增殖必需基因E1a,使病毒能在癌细胞内特异性增殖复制;以此溶瘤腺病毒为载体,表达一种人工合成的LncRNA编码序列,该LncRNA编码序列包含一组能够通过多种机制促进癌细胞发生发展的OncomiRs的种子序列的互补结合序列;随腺病毒在癌细胞内特异性高拷贝复制,实现LncRNA在癌细胞内大量表达和高拷贝积累,通过与OncomiRs的靶基因竞争性结合并消耗OncomiRs,从而保护细胞内大量的抑癌基因免受OncomiRs的干扰和抑制,实现对癌细胞的靶向干预治疗。这样的策略由于其病毒载体的肿瘤靶向特异性增殖和针对OncomiRs致癌作用的特异性干预,因而使其抗肿瘤疗效得以提高,安全性得以改善。
LncRNA编码序列
所述的“LncRNA编码序列”即编码LncRNA的DNA序列。作为本发明的一个优选例,LncRNA的编码序列如SEQ ID NO.1所示。作为本发明的一种具体实施方式,LncRNA的编码序列如SEQ ID NO.2所示,且为了使LncRNA的编码序列能够得到比较强的转录活性,防止其翻译,在SEQ ID NO.2所示序列的5’-端加入了CACCATGC,在3’-端加入AG,增加后的LncRNA编码序列如SEQ ID NO.3所示。以上序列的引物是为了在LncRNA编码序列的起始和终止位置增加翻译终止密码子,该终止密码子可以是TAG、TGA或TAA。
本发明的LncRNA编码序列优选为人工合成的方法获得。
作为本发明的一种具体实施方式,所述的LncRNA编码序列包含一组OncomiRs的种子序列的互补结合序列,该组OncomiRs在肝癌细胞中高水平表达,能够通过多种机制促进肝癌细胞发生发展。该组OncomiRs包括miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR106b、miR-151-5p、miR-155、miR-181a/181b、miR-184、miR-1、miR-449a。它们在肝癌的发生发展中分别作用于不同的靶基因和信号传导途径,分别起不同的作用。如:肝癌中miR-21高表达可抑制抑癌基因PTEN的表达,PTEN蛋白是3-磷酸肌醇激酶(phosphoinositide 3-kinase,PI3K)/丝/苏氨酸蛋白激酶(serine/threonine kinase,AKT)通路的重要抑制蛋白,因此,miR-21抑制PTEN的后果即是激活PI3K/AKT通路,促进癌细胞的增殖、转移;miR-221/222作用于许多关键的肿瘤抑制因子,包括Bmf、p27Kip1、p57Kip2l6、PTEN、金属蛋白酶-3的组织抑制因子TIMP-3以及DNA损伤诱导转录子4(DDIT4),从而介导肿瘤的发生发展。将这些miRNAs按功能分类,肝癌中miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR106b、miR-151-5p、miR-155、miR-181a/181b、miR-184高表达则能够促进癌细胞增殖、侵袭、转移;miR-221/222、miR-224、miR-10b、miR-155高表达能够抑制癌细胞凋亡;miR-21、miR-221/222、miR-143、miR-1、miR-449a高表达能够促进乙肝病毒增殖,诱导细胞癌变和增强癌细胞增殖活性。抑制这些有致癌、促癌活性的miRNAs的表达及功能,可通过多种途径多种效应抑制肝癌的发生发展。
本发明不仅限于此,所述的LncRNA的编码序列还可以包含一个或一组OncomiRs的种子序列的互补结合序列,所述的OncomiRs既可以是一个或一组在肝癌之外其他肿瘤中高表达、并能够通过多种机制促进肝癌之外其他肿瘤发生发展的OncomiRs,也可以是针对肝癌除miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR-151-5p、miR-155、miR-181a/181b、miR-184、miR-1、miR-449a、miR106b之外的一个或一组OncomiRs。
LncRNA
长链非编码RNA(Long non-coding RNA,LncRNA)是长度在200-100000nt之间的RNA分子,不编码蛋白,参与细胞内多种过程调控。
本发明的LncRNA由包含一组能够通过多种机制促进肝癌细胞发生发展的OncomiRs的种子序列互补结合序列的DNA序列编码获得。作为本发明的一个优选例,编码得到的LncRNA序列如SEQ ID NO.4所示。作为本发明的一种具体实施方式,以上LncRNA的编码序列在病毒的基因组中重复6倍,编码得到的LncRNA序列如SEQ ID NO.5所示,以提高竞争性结合相应OncomiRs的效果。
LncRNA编码序列的启动子
所述的“LncRNA编码序列的启动子”用于启动LncRNA编码序列的转录,其包含其它的具备相同功能的顺式作用元件。本发明的LncRNA编码序列在病毒的基因组中可以受以下任意一种启动子或顺式元件的调控:(a)癌胚抗原启动子;(b)甲胎蛋白启动子;(c)人表皮生长因子受体家族(EGFRs)的受体酪氨酸激酶(包括EGFR、Her-2、Her-3和Her-4)启动子;(d)乳腺癌相关抗原DF3/MUC1启动子;(e)血管内皮生长因子(VEGF)受体KDR的启动子;(f)单纯疱疹病毒启动子;(g)E2F启动子;(h)前列腺素特异性抗原的启动子。作为本发明的一个优选例,所述的LncRNA编码序列受鼠巨细胞病毒(CMV)启动子的控制,该顺式作用元件插入LncRNA编码序列的转录起始位点之前,保证LncRNA在病毒感染的肿瘤内部高效表达,发挥生物学活性。所述的CMV启动子的序列优选如SEQ ID NO.6所示。
肿瘤特异性启动子
所述的肿瘤特异性启动子为一种肿瘤特异性的调控序列。由于许多肿瘤都有其自身特异性的肿瘤标志物,其表达受该肿瘤特异性顺式作用元件或反式作用因子的调控,因此,将病毒增殖基因置于此类肿瘤特异性调控序列的调控之下,可使病毒选择性地在相应的组织细胞中增殖,而不影响其它组织细胞。
本发明所述的肿瘤特异性启动子可以由以下任何一组启动子和增强子构成:(a)癌胚抗原启动子、增强子及其突变体序列;(b)甲胎蛋白启动子、增强子及其突变体序列;(c)人表皮生长因子受体家族(EGFRs)的受体酪氨酸激酶(包括EGFR、Her-2、Her-3和Her-4)启动子、增强子及其突变体序列;(d)乳腺癌相关抗原DF3/MUC1启动子、增强子及其突变体序列;(e)血管内皮生长因子(VEGF)受体KDR的启动子、增强子及其突变体序列;(f)L-plastin启动子、增强子及其突变体序列;(g)凋亡抑制蛋白家族(IAP)成员的启动子、增强子及其突变体序列;(h)前列腺素特异性抗原的启动子、增强子及其突变体序列;(i)缺氧诱导因子-1(HIF-1)调控的缺氧反应元件保守序列;(j)转录因子E2F启动子、增强子及其突变体序列。
凋亡抑制因子Survivin属于凋亡抑制蛋白因子(IAP)家族成员,参与调节胚胎细胞生理发育和细胞周期调控的各个方面,通过多种途径抑制细胞凋亡,促进细胞增殖和周期进展。Survivin表达于胚胎发育组织和大多数肿瘤组织,但在正常成人组织不表达。Survivin在恶性肿瘤中的表达具有高度选择性,在人类最常见的绝大多数肿瘤组织如肺癌、结肠癌、胰腺癌、前列腺癌和乳腺癌以及非霍奇金淋巴瘤中都呈高表达,并且与肿瘤的复发转移以及患者的预后不佳有一定关系,使其成为一种广谱的肿瘤诊断标志物。因此,以Survivin启动子调控的病毒,有望实现针对大多数人体肿瘤的广谱的抗癌效应。
作为本发明的一个优选例,以Survivin启动子核心序列为顺式作用元件,插入腺病毒增殖必需基因E1a的转录起始位点与翻译起始位点ATG之间,调控E1a转录激活,使E1a只能特异性地在Survivin阳性的肿瘤细胞内表达,而对正常细胞没有影响或者影响极弱,其调控具有更好的可靠性和安全性。本发明采用的肿瘤特异性Survivin基因启动子的序列如SEQ ID NO.7所示。
病毒增殖必需基因
病毒增殖必需基因为病毒的增殖复制提供所必需的蛋白。腺病毒增殖必需基因包括E1a,还包括Elb-55kDa、Elb-19kDa、E3或E4。Elb-55kDa是腺病毒在正常细胞增殖复制必需的而在肿瘤细胞中不必需的蛋白,Elb-55kDa编码基因的选择性缺失可以使腺病毒在肿瘤细胞内保持增殖复制的能力,而在正常细胞中失去复制能力。Elb-55kDa能够灭活并降解P53蛋白,Elb-55kDa编码基因的选择性缺失有利于细胞保持P53蛋白的抗肿瘤活性,同时提高病毒载体的靶向性。腺病毒Elb-19kDa编码基因与凋亡抑制基因Bcl-2同源,编码的Elb-19kDa能够结合Bax或/和Bak启动下游的凋亡抑制程序,Elb-19kDa还可以破坏Fas介导的凋亡过程,保护感染的细胞免受TNF-α介导的杀伤作用。
作为本发明的一个优选例,所述的病毒增殖必需基因E1a序列如SEQ ID NO.8所示。
重组溶瘤腺病毒
本发明使用重组病毒载体介导LncRNA编码序列在肿瘤细胞的特异性表达,以发挥抗癌作用。所述的重组病毒载体可由现有的病毒载体、肿瘤特异性启动子和LncRNA的表达盒构建而成,所述的LncRNA的表达盒包含LncRNA编码序列及该LncRNA编码序列的启动子。
人类溶瘤腺病毒有A、B、C、D、E、F 6个不同亚属,它们对宿主细胞的亲嗜性、致瘤性及疾病史各不相同。本发明优选使用溶瘤腺病毒C亚属中的5型。
作为本发明的一个优选例,所述的重组溶瘤腺病毒由人类5型腺病毒、肿瘤特异性启动子和LncRNA的表达盒构建而成。该重组溶瘤腺病毒由含5型腺病毒基因组的骨架质粒pBHGloxdeltaE1,3Cre与携带LncRNA编码序列的腺病毒穿梭质粒在293细胞内通过Cre-loxP重组酶切割系统定点重组而产生。所述的重组溶瘤腺病毒的重组区以外的序列与pBHGloxdeltaE1,3Cre腺病毒载体重组区以外的序列一致,所述的重组溶瘤腺病毒的重组区内的序列如SEQ ID NO.9所示。
其中:(1)1-6bp:XbaI酶切位点;(2)7-996bp:Survivin启动子序列;(3)997-1002bp:EcoRI酶切位点;(4)1003-1991bp:E1a基因cDNA序列;(5)1992-2301bp:SV40PolyA加尾序列;(6)2302-2307bp:BamHI酶切位点;(7)2308-2838bp:鼠巨细胞病毒(CMV)启动子序列;(8)2339-2844bp:SalI酶切位点;(9)2845-2851bp:LncRNA转录起始位点;(10)2852-4030bp:6个重复拷贝的LncRNA编码序列;(11)4031-4190bp:LncRNA加尾序列;(12)4191-4196bp:SalI酶切位点。
所述的重组溶瘤腺病毒的全基因组序列如SEQ ID NO.10所示,且实施例中最终构建的重组溶瘤腺病毒的全基因组序列以SEQ ID NO.10为准。
实施例1肿瘤特异性Survivin启动子控制E1a的腺病毒质粒的构建
第一步:人工合成肿瘤特异性Survivin启动子,5’-端引入XbaI位点,3’-端引入EcoRI位点,插入质粒pDC315的XbaI+EcoRI位点,构建含Survivin启动子的质粒pDC315-SVP。pDC315为加拿大Microbix Biosystems公司产品(产品目录号:PD-01-27)。设计合成的Survivin启动子全长1002bp,序列是在SEQ ID NO.7的5’-端引入XbaI酶切位点(TCTAGA);在3’-端引入EcoRI酶切位点(GAATTC)。
第二步:克隆获得腺病毒E1a序列(含PolyA加尾序列),5’-端引入EcoRI位点和ACC,3’-端引入BamHI位点,插入pDC315-SVP的EcoRI+BamHI位点,构建成肿瘤特异性Survivin启动子控制E1a表达的质粒pDC315-SVPE1a。E1a(含PolyA加尾序列)全长1311bp,其中,第1-6bp:EcoRI酶切位点(GAATTC);第7-9bp:ACC;第10-995bp:E1a基因cDNA序列(SEQID NO.8);第996-1305bp:SV40PolyA加尾序列(SEQ ID NO.11);第1306-1311bp:BamHI酶切位点(GGATCC)。
实施例2表达人工合成的长链非编码RNA(LncRNA)的腺病毒包装质粒的构建
第一步:克隆获得鼠巨细胞病毒(CMV)启动子序列,5’-端引入BamHI位点,3’-端引入SalI位点,插入质粒pDC315的BamHI+SalI位点,构建成含mCMV启动子的质粒pDC315-mCMV。mCMV序列长543bp,其中,第1-6bp:BamHI酶切位点(GGATCC);第7-537bp:鼠巨细胞病毒(CMV)启动子序列(SEQ ID NO.6);第538-543bp:SalI酶切位点(GTCGAC)。
第二步:人工合成编码LncRNA的6个拷贝的DNA序列(含PolyA加尾序列),5’-端和3’-端均引入SalI位点,插入pDC315-mCMV的SalI位点,构建成含LncRNA编码序列的表达质粒pDC315-mCMVLncR。编码LncRNA的DNA序列(含PolyA加尾序列)长1348bp,其中,第1-6bp:SalI酶切位点(GTCGAC);第7-13bp:转录起始位点(CACCATG);第14-1192bp:含有6个重复拷贝的LncRNA编码序列(SEQ ID NO.12);第1193-1352bp:LncRNA加尾序列(SEQ ID NO.13);第1353-1358bp:SalI酶切位点(GTCGAC)。
第三步:pDC315-mCMVLncR经BamHI+SalI酶切,回收含有LncRNA完整表达框的片段,插入pDC315-SVPE1a质粒的BamHI+SalI位点,构建携带LncRNA编码序列的肿瘤特异性增殖腺病毒包装质粒pDC315-SVPE1a-mCMVLncR。LncRNA完整表达框全长1895bp,其中,第1-6bp:BamHI酶切位点;第7-537bp:鼠巨细胞病毒(CMV)启动子序列(SEQ ID NO.6);第538-543bp:SalI酶切位点;第544-550bp:转录起始位点(CACCATG);第551-1729bp:含有6个重复拷贝的LncRNA编码序列(SEQ ID NO.12);第1730-1889bp:LncRNA加尾序列(SEQ IDNO.13);第1890-1895bp:SalI酶切位点。
实施例3携带LncRNA编码序列的肿瘤特异性增殖腺病毒的重组、扩增和纯化
第一步:将构建好的5型腺病毒左臂包装质粒pDC315-SVPE1a-mCMVLncR与5型腺病毒右臂包装质粒pBHGloxdelE13cre通过LipoFectamine2000共转染HEK293细胞。转染具体方法步骤参见Invitrogen公司的LipoFectamine2000试剂盒操作说明书。质粒pBHGloxdelE13cre和HEK293细胞株为加拿大Microbix Biosystems公司产品。pBHGloxdelE13cre含有5型腺病毒右臂,缺失E1、E3区,其重组酶系统Cre/LoxP可以保证病毒的高效重组。HEK293细胞由剪切的5型腺病毒DNA转化,含5型腺病毒E1区,腺病毒DNA对其具有高转染效率,能够促进腺病毒的重组和包装。在载体共转染后的14天出现病毒空斑,经过三次病毒空斑纯化(具体方法参见GeneTransfer and Expression Protocols,MurrayEJ主编,Humana Press,Clifton,New Jersey),重组出腺病毒AdSVPE1a-lncR。
完整的腺病毒AdSVPE1a-lncR基因组序列如SEQ ID NO.10所示。其中:(1)1-85bp:5型腺病毒ITR序列;(2)86-437bp:5型腺病毒基因组序列;(3)438-443bp:XbaI酶切位点;(4)444-1433bp:Survivin启动子序列;(5)1434-1439bp:EcoRI酶切位点;(6)1440-2428bp:E1a基因cDNA序列;(7)2429-2738bp:SV40PolyA加尾序列;(8)2739-2744bp:BamHI酶切位点;(9)2745-3275bp:鼠巨细胞病毒(CMV)启动子序列;(10)3276-3281bp:SalI酶切位点;(11)3282-3288bp:LncRNA转录起始位点;(12)3289-4467bp:含有6个重复拷贝的LncRNA编码序列;(13)4468-4627bp:LncRNA加尾序列;(14)4628-4633bp:SalI酶切位点;(14)4634-4668bp:LoxP序列;(15)4669-34339bp:5型腺病毒基因组序列;(16)34340-34441bp:5型腺病毒ITR序列。
第二步:腺病毒AdSVPE1a-lncR在HEK293细胞中大量繁殖,应用氯化铯梯度离心的方法大量纯化腺病毒(具体方法参见GeneTransfer and Expression Protocols,MurrayEJ主编,Humana Press,Clifton,New Jersey)。
实施例4重组腺病毒AdSVPE1a-lncR的鉴定
重组腺病毒AdSVPE1a-lncR的插入序列通过测序和PCR证实。AdSVPE1a-lncR为5型腺病毒,插入序列包括6个拷贝的LncRNA编码序列、mCMV启动子、Survivin启动子、E1a序列,其他DNA序列与5型腺病毒相同。鉴定所用PCR引物如表1所示:
表1.重组腺病毒AdSVPE1a-lncR鉴定的PCR引物
结果:以上述引物序列进行PCR,均能扩增出与理论长度相同的目的条带,且测序正确。
实施例5重组腺病毒AdSVPE1a-lncR在肝癌细胞中的增殖及基因表达实验
第一步:重组腺病毒AdSVPE1a-lncR的特异性增殖。收集对数生长期的肝癌细胞(HepG2、Hep3B、SMMC-7721、MHCC97H、MHCC97L、Huh-7、PLC/PRF/5)和正常肝细胞(L02、WRL-68),计数,铺96孔板,1×104/孔,细胞贴壁后,换用无血清培养液;以MOI=1加入AdSVPE1a-lncR。病毒感染2h后调节至5%血清培养液,继续培养12h、24h、48h、72h,分别在这三个时间段收集细胞,TCID50方法检测病毒滴度。结果显示:AdSVPE1a-lncR在HepG2、Hep3B、MHCC97H、Huh-7、PLC/PRF/5中特异性增殖复制的能力非常强,72h后可达数千至数万倍,最高达68465.66倍(Huh-7),在SMMC-7721、MHCC97L中达数百倍,而在正常细胞中L02、WRL-68增殖不明显,在10倍以下(图1)。
第二步:LncRNA的特异性高效表达。上述细胞以MOI=1感染实验腺病毒AdSVPE1a-lncR,培养48h后收集细胞,实时定量RT-PCR检测LncRNA的表达,LncRNA特异性PCR引物为LncR-F(5’-CTGCACTGTCAGCACTTTA-3’)和LncR-R(5’-ACATTCATTGCTGTCGGTG-3’)。结果显示:AdSVPeGFP-lncR介导的LncRNA表达水平,在Huh-7、Hep3B、HepG2中最高,其次为PLC/PRF/5、MHCC97H、BEL-7402、MHCC97L、SMMC-7721,在正常肝细胞L02和WRL-68中表达量极低(图2)。
实施例6重组腺病毒AdSVPE1a-lncR对肝癌细胞生物学行为的影响
第一步:LncRNA表达对细胞增殖活性的影响。通过四唑盐比色实验(MTT)检测病毒AdSVPE1a-lncR对肿瘤细胞和正常细胞的作用。Cell Proliferation Kit I(MTT)购于Roche Diagnostics GmbH。收集对数生长期的细胞,计数,用10%血清培养液稀释细胞,1×104细胞数/100μl/孔,传至96孔板;细胞贴壁后,以无血清培养液稀释病毒,按MOI=1~100pfu/cell的感染强度加入相应病毒100μl,对应于每个病毒设8个复孔,孵箱内培养2h;换血清培养液100μl/孔,培养48h后,弃培养液,加入0.1mol/L PBS溶液100μl/孔,再加MTTlabeling reagent 10μl/孔至终浓度0.5mg/ml,置孵箱内4h;加Solubilization solution(10%SDS in 0.01mol/L HCl)100μl/孔,置孵箱内过夜;采用Model 550MicroplateReader(BIO-RAD)测定570nm波长光吸收值,校正波长为655nm;绘制曲线。结果显示:AdSVPE1a-lncR对Hep3B和Huh-7杀伤活性最强,Hep3B存活率在MOI=2pfu/cell时已下降到10%以下,在MOI=0.5pfu/cell时已下降到50%以下;Huh-7存活率在MOI=100pfu/cell时已下降到10%以下,在MOI=1pfu/cell时已下降到50%以下。AdSVPE1a-lncR对HepG2和MHCC97L的杀伤,在MOI=20pfu/cell时存活率下降到50%以下;AdSVPE1a-lncR对PLC/PRF/5的杀伤,在MOI=50pfu/cell时存活率下降到50%以下;AdSVPE1a-lncR对MHCC97H和SMMC-7721的杀伤,在MOI=100pfu/cell时存活率下降到50%以下;AdSVPE1a-lncR对BEL-7402的杀伤活性较弱,在MOI=200pfu/cell时存活率才下降到50%以下。AdSVPE1a-lncR对正常肝细胞无明显影响,在MOI=500以下细胞存活率一直维持在80%以上。
第二步:LncRNA表达对细胞迁移侵袭能力的影响。实验组为以MOI=10pfu/cell感染AdSVPE1a-lncR病毒的肿瘤细胞(ER1组),以AdSVPeGFP-lncR为阳性病毒对照(ER2组,表达LncRNA的非增殖病毒),以Ad5-eGFP为阴性病毒对照(CR1组,不表达LncRNA的非增殖病毒),另设不加病毒的细胞同步培养作为空白对照(CR2组)。将Transwell小室置于24孔板中,在小室的上室加入细胞,每小室加入4×105细胞数/200μl,下室中加入500μl含10%胎牛血清的培养基。观察细胞侵袭力时上室加聚碳酸酯膜基质胶,观察细胞迁移力时不加基质胶。细胞培养24h后取出,擦去小室上层细胞,用0.1%结晶紫染色20min,光学显微镜下随机取3个视野(×200倍)进行计数并拍照,实验重复3次。结果显示:AdSVPE1a-lncR能够明显抑制肝癌细胞的迁移侵袭能力,AdSVPeGFP-lncR也有抑制肝癌细胞迁移侵袭力的活性,但活性弱于AdSVPE1a-lncR。AdSVPE1a-lncR和AdSVPeGFP-lncR对正常肝细胞无明显作用(图4)。
实施例7重组腺病毒AdSVPE1a-lncR对肝癌细胞基因表达谱的影响
收集对数生长期的Huh-7细胞,1×106细胞数/100μl/孔,传至24孔板;细胞贴壁后,以无血清培养液稀释病毒,按MOI=10pfu/cell的感染强度加入AdSVPE1a-lncR病毒100μl,设Ad5-eGFP为阴性病毒对照,不加病毒的细胞同步培养作为空白对照。孵箱内培养2h;换血清培养液100μl/孔,培养48h后,收集细胞,提取细胞总蛋白,基因表达谱芯片检测蛋白表达的变化。空白对照组以cy3荧光信号标记为绿色,实验组以cy5荧光信号标记为红色。两组荧光信号叠加,在cy3信号较强时显绿色,差值低于0.5倍提示基因表达呈下调趋势;在cy5信号较强时显红色,差值达2倍提示基因表达呈上调趋势;cy3和cy5信号强度相似,即显示黄色,变化趋势在0.5倍至2倍之间。实验结果显示:Huh-7感染AdSVPE1a-lncR后,基因表达谱变化明显。检出升高表达者708个基因,其中原癌基因和抑癌基因类13个,离子通道和运输蛋白类11个,细胞周期蛋白类12个,细胞骨架及运动蛋白类13个,细胞凋亡相关蛋白类5个,DNA合成修复及重组蛋白类6个,DNA结合及转录因子类30个,细胞受体类10个,免疫相关蛋白类27个,细胞信号及传导蛋白类74个,代谢分子61个,蛋白翻译合成因子类48个,分化发育相关类9个,其他类分子389个;检出降低表达者628个基因,其中原癌基因和抑癌基因类12个,离子通道和运输蛋白类14个,细胞周期蛋白类21个,细胞骨架及运动蛋白类32个,细胞凋亡相关蛋白类5个,DNA合成修复及重组蛋白类7个,DNA结合及转录因子类17个,细胞受体类12个,免疫相关蛋白类31个,细胞信号及传导蛋白类59个,代谢分子63个,蛋白翻译合成因子类48个,分化发育相关类8个,其他类分子299个。图5显示一些代表性基因表达水平的变化,其中上调比较明显的是PTEN、p27kip1、TIMP3、RECK,下调比较明显的是p38/MAPK、Survivin、CDK4、c-myc(图5)。
实施例8重组腺病毒AdSVPE1a-lncR对肝癌裸鼠移植瘤的抑制作用
健康纯种BALB/C裸鼠40只,5周龄,雄性,中科院上海斯莱克实验动物中心提供,合格证号SCXK(沪)2012-0002。取对数生长期Huh-7细胞悬液注射于裸鼠右腋皮下,5×106细胞数/100μl/只。接种后10天,成瘤率100%,移植瘤直径大约0.8-1.0cm。随机分为4组(AdSVPE1a-lncR、AdSVPeGFP-lncR、Ad5-eGFP、空白对照组)。病毒治疗组给予相应腺病毒瘤内多点注射,每次每只剂量2×108pfu/100μl,隔天一次,共5次;空白对照组同步注射生理盐水,每次每只100μl。治疗后,每周测量瘤体大小,以“最大径×最小径2×0.5”公式计算瘤体体积,绘制生长曲线。
至治疗后第14天,AdSVPE1a-lncR治疗组肿瘤生长速度已明显低于空白对照组,至第21天,肿瘤体积出现下降;AdSVPeGFP-lncR组在治疗后28天也出现一定程度的生长抑制,与空白对照组相比,差别具有显著意义,但瘤体仍在持续增长中;Ad5-eGFP组自始至终未出现生长抑制(表2)。观察至治疗后42天,AdSVPE1a-lncR组瘤体体积已明显低于治疗前(图6)。终止观察,无痛处死裸鼠。
表2.AdSVPE1a-lncR对Huh-7肝癌细胞裸鼠移植瘤的抑瘤效果
注:*与同一时间点的对照组相比,T检验。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (10)
1.一种竞争性消耗致癌性microRNAs的LncRNA,其特征在于,所述的LncRNA的序列为SEQ ID NO.4所示序列的n个拷贝,其中,n为大于等于1的整数。
2.编码权利要求1所述的LncRNA的编码序列,其特征在于,所述的编码序列为SEQ IDNO.1所示序列的n个拷贝,其中,n为大于等于1的整数。
3.一种溶瘤腺病毒,其特征在于,所述的溶瘤腺病毒的基因组中整合有权利要求1所述的LncRNA的表达盒。
4.根据权利要求3所述的溶瘤腺病毒,其特征在于,所述的LncRNA的表达盒包含权利要求2所述的LncRNA的编码序列,以及调控LncRNA的编码序列表达的启动子,所述的调控LncRNA的编码序列表达的启动子插入在所述LncRNA的编码序列的转录起始位点之前。
5.根据权利要求4所述的溶瘤腺病毒,其特征在于,所述的溶瘤腺病毒的基因组中含有病毒增殖必需基因和调控所述病毒增殖必需基因表达的肿瘤特异性启动子。
6.根据权利要求5所述的溶瘤腺病毒,其特征在于,所述的溶瘤腺病毒是以人类5型腺病毒为基础构建而成;所述的调控LncRNA的编码序列表达的启动子序列如SEQ ID NO.6所示,所述的病毒增殖必需基因序列如SEQ ID NO.8所示,所述的肿瘤特异性启动子序列如SEQ ID NO.7所示。
7.根据权利要求3所述的溶瘤腺病毒,其特征在于,所述的溶瘤腺病毒的全基因组序列如SEQ ID NO.10所示。
8.权利要求1所述的LncRNA、权利要求2所述的LncRNA的编码序列或权利要求3-7任一所述的溶瘤腺病毒在制备药物中的用途,其特征在于,所述的药物用于治疗肿瘤。
9.根据权利要求8所述的用途,其特征在于,所述的肿瘤中miR-21、miR-221/222、miR-224、miR-17-5p、miR-10b、miR106b、miR-151-5p、miR-155、miR-181a/181b、miR-184、miR-1和/或miR-449a高表达。
10.权利要求1所述的LncRNA、权利要求2所述的LncRNA的编码序列或权利要求3-7任一所述的溶瘤腺病毒在制备试剂中的用途,其特征在于,所述的试剂用于研究肝癌细胞中的分子作用机制或/和肝癌的治疗。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510056926.7A CN104651364B (zh) | 2015-02-04 | 2015-02-04 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
PCT/CN2015/091892 WO2016124002A1 (zh) | 2015-02-04 | 2015-10-14 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
US15/523,422 US10323244B2 (en) | 2015-02-04 | 2015-10-14 | LncRNA and oncolytic adenovirus, and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510056926.7A CN104651364B (zh) | 2015-02-04 | 2015-02-04 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104651364A CN104651364A (zh) | 2015-05-27 |
CN104651364B true CN104651364B (zh) | 2017-07-07 |
Family
ID=53243009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510056926.7A Expired - Fee Related CN104651364B (zh) | 2015-02-04 | 2015-02-04 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10323244B2 (zh) |
CN (1) | CN104651364B (zh) |
WO (1) | WO2016124002A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104651364B (zh) | 2015-02-04 | 2017-07-07 | 中国人民解放军第二军医大学 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
CN110832072B (zh) * | 2017-04-21 | 2023-11-07 | 真基因太科公司 | 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法 |
CN108085394A (zh) * | 2018-02-05 | 2018-05-29 | 苏州吉玛基因股份有限公司 | 与肝癌诊疗相关的血清外泌体hsa-miR-17-5p及其应用 |
CN110527682B (zh) * | 2018-05-25 | 2023-09-01 | 中国科学院深圳先进技术研究院 | 一种长链非编码rna及其应用 |
CN110403953A (zh) * | 2019-04-29 | 2019-11-05 | 中国人民解放军南部战区总医院 | miRNA-21的抑制剂在乙型肝炎治疗中的应用 |
CN114231626A (zh) * | 2021-10-14 | 2022-03-25 | 杭州师范大学 | 一种miRNA联合标志物在制备诊断检测早期肝癌的试剂盒中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103937796A (zh) * | 2014-04-16 | 2014-07-23 | 宁波大学 | 一对胃癌发生相关的竞争性内源rna |
CN104178460A (zh) * | 2014-07-18 | 2014-12-03 | 上海市第一人民医院 | 一种受转录和转录后双调控的溶瘤腺病毒及其构建方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013134558A1 (en) * | 2012-03-07 | 2013-09-12 | The Texas A & M University System | Cancer treatment targeting non-coding rna overexpression |
US20150329858A1 (en) | 2012-11-16 | 2015-11-19 | The University Of Tokyo | Long non-coding rna used for anticancer therapy |
CN104651364B (zh) * | 2015-02-04 | 2017-07-07 | 中国人民解放军第二军医大学 | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 |
-
2015
- 2015-02-04 CN CN201510056926.7A patent/CN104651364B/zh not_active Expired - Fee Related
- 2015-10-14 US US15/523,422 patent/US10323244B2/en active Active
- 2015-10-14 WO PCT/CN2015/091892 patent/WO2016124002A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103937796A (zh) * | 2014-04-16 | 2014-07-23 | 宁波大学 | 一对胃癌发生相关的竞争性内源rna |
CN104178460A (zh) * | 2014-07-18 | 2014-12-03 | 上海市第一人民医院 | 一种受转录和转录后双调控的溶瘤腺病毒及其构建方法 |
Non-Patent Citations (3)
Title |
---|
Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma;Jin-Lan Huang et al.;《Carcinogenesis》;20131202;第35卷(第3期);507-514 * |
Stable knockdown of microRNA in vivo by lentiviral vectors;Bernhard Gentner et al.;《NATURE METHODS》;20090131;第6卷(第1期);63-66 * |
Use of MicroRNA Let-7 to Control the Replication Specificity of Oncolytic Adenovirus in Hepatocellular Carcinoma Cells;Huajun Jin et al.;《PLoS ONE》;20110721;第6卷(第7期);e21307 * |
Also Published As
Publication number | Publication date |
---|---|
US10323244B2 (en) | 2019-06-18 |
US20170314018A1 (en) | 2017-11-02 |
WO2016124002A1 (zh) | 2016-08-11 |
CN104651364A (zh) | 2015-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104651364B (zh) | 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途 | |
Sun et al. | Effect of exosomal miRNA on cancer biology and clinical applications | |
EP2559442B1 (en) | Method for regulating microrna content in organisms and uses thereof | |
Friedman et al. | MicroRNAs: critical mediators of differentiation, development and disease | |
AU2015309403B2 (en) | Use of alphavirus in preparation of antitumor drugs | |
Spence et al. | MicroRNAs in nasopharyngeal carcinoma | |
Feng et al. | Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment | |
Tang et al. | microRNA inhibitors: Natural and artificial sequestration of microRNA | |
CN102782155B (zh) | 用于肺癌的血浆中微rna表达谱分析的组合物和方法 | |
BR112020001559A2 (pt) | vetores virais oncolíticos e usos dos mesmos | |
Varshney et al. | MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics | |
Zhang et al. | Therapeutics based on microRNA: a new approach for liver cancer | |
Vahabi et al. | MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies | |
Adil et al. | Targeting Akt-associated microRNAs for cancer therapeutics | |
Díaz-González et al. | Utility of microRNAs and siRNAs in cervical carcinogenesis | |
Cortez et al. | microRNAs in cancer: from bench to bedside | |
Feng et al. | RETRACTED ARTICLE: Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma | |
Chen et al. | Differential microRNA expression in Newcastle disease virus-infected HeLa cells and its role in regulating virus replication | |
Liu et al. | Role of microRNAs in hepatocellular carcinoma | |
Alvanegh et al. | Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer | |
CN107488733B (zh) | miR-133b在前列腺癌骨转移诊断、预测、治疗中的应用 | |
CN102433383B (zh) | 人stim1基因的用途及其相关药物 | |
CN102102102B (zh) | hsa-miR-185的新用途 | |
CN103484462B (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
Peter et al. | A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170707 |
|
CF01 | Termination of patent right due to non-payment of annual fee |